COLL - Collegium Pharmaceutical, Inc.
Freestone Grove Partners LP bought a new stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ: COLL) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 44,493 shares of the specialty pharmaceutical company's stock, valued at approximately $1,611,000. Freestone Grove Partners LP owned
BlackRock Inc. bought a new position in Collegium Pharmaceutical, Inc. (NASDAQ: COLL) during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 5,441,202 shares of the specialty pharmaceutical company's stock, valued at approximately $196,972,000. BlackRock Inc. owned about 16.78% of Collegium
On August 27, 2026, Collegium Pharmaceutical Inc (COLL) shares fell 3.9% to a current price of $26.39. Over the past year, the stock has seen significant volati
STOUGHTON, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and often misunderstood conditions, today announced that it has entered into an Accelerated Share Repurchase ("ASR") agreement with Jefferies LLC to repurchase $50 million of the Company's common stock. Collegium will execute the ASR as part of the $150 million share repurchase program authorized by its Board of Directors in July 2025. Upon completion of this ASR, Collegium will have $100 million remaining under the program.
Collegium Pharmaceutical (NASDAQ: COLL - Get Free Report) and Avenue Therapeutics (NASDAQ: ATXI - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, profitability, dividends, valuation, analyst recommendations and institutional ownership. Profitability This table compares Collegium Pharmaceutical and
Collegium Pharmaceutical, Inc. (COLL) Q2 2026 Earnings Call Transcript
Although the revenue and EPS for Collegium Pharmaceutical (COLL) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Collegium Pharmaceutical (COLL) came out with quarterly earnings of $1.92 per share, beating the Zacks Consensus Estimate of $1.68 per share. This compares to earnings of $1.68 per share a year ago.
Collegium Pharmaceutical NASDAQ: COLL reported second-quarter 2026 net product revenue of $199.9 million, up 6% from a year earlier, as growth in its ADHD franchise and BELBUCA helped offset lower revenue from the NUCYNTA pain franchise.
– Completed Acquisition of AZSTARYS ® , Strengthening ADHD Portfolio and Extending Long-Term Revenue Outlook – – Generated Quarterly Net Revenues of $199.9 Million, Up 6% Year-over-Year – – Generated JORNAY PM ® Quarterly Net Revenue of $46.1 Million, Up 41% Year-over-Year – – Generated AZSTARYS Quarterly Net Revenue of $12.9 Million, Representing a Partial Quarter of Sales – – Generated Quarterly Pain Portfolio Net Revenues of $140.9 Million – – Updates Full-Year 2026 Financial Guidance – – Conference Call Scheduled for Today at 8:00 a.m. ET – STOUGHTON, Mass.
Collegium Pharmaceutical (COLL) is transitioning from a pain-management roll-up to a CNS platform, leveraging stable pain cash flows to fuel ADHD franchise growth. The AZSTARYS acquisition, funded with $350M cash and $300M debt, is expected to deliver $60–70M revenue in 2026 and $50M+ annual synergies within 12 months. COLL's 2026 guidance is $865–895M in revenue and $475–500M adjusted EBITDA, with a 55% margin, reflecting only partial-year AZSTARYS contribution and early synergies.
STOUGHTON, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and often misunderstood conditions, today announced that it will report second quarter 2026 financial results before the market opens on Thursday August 6, 2026.
Bessemer Group Inc. grew its stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ: COLL) by 48.0% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 98,020 shares of the specialty pharmaceutical company's stock after purchasing an additional 31,800 shares during the quarter. Bessemer
BOSTON--(BUSINESS WIRE)--DivcoWest, a DivCore Capital company and national commercial real estate investment firm, today announced that Collegium Pharmaceutical, a leading biopharmaceutical company, has signed a lease for 40,288 square feet on floors 11 and 12 at One Lincoln in Boston's Financial District. The 36‑story, 1.1‑million‑square‑foot Class A office tower completed a transformative renewal in 2025 and now serves as a landmark next-generation workplace for world-class established and gr.
STOUGHTON, Mass., July 20, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) a leading biopharmaceutical company focused on improving the lives of people living with serious and often misunderstood conditions, today announced plans to relocate its corporate headquarters to One Lincoln in downtown Boston in the first quarter of 2027.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
COLL, IRWD, AMTB and DUK stand out as defensive stock picks as investors rotate from AI-driven tech amid the ongoing sell-off and seek safer sectors.
BBCP, KUBTY, ADM, COLL and W have been added to the Zacks Rank #1 (Strong Buy) List on July 6, 2026.
COLL gains momentum as strong Jornay PM growth and the Azstarys acquisition boosted 2026 guidance, strengthening its ADHD franchise and revenue outlook.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.